Ebastine fast-dissolving tablets versus regular tablets: Acceptability and preference in patients with allergic rhinitis

Expert Review of Clinical Pharmacology

Volumn 1, Issue 3, 2008, Pages 381-389

  Roger, A ^a   Fortea, Josep ^b   Mora, S ^b   Artes M ^c  

^a Centre Roger Barri d Asmologia i Al lèrgia   (Spain)

^b Almirall SA ^*  (Spain)

^c Adelphi Targis SL ^*  (Spain)

Author keywords

Allergy; Compliance; Ebastine; Fast dissolving tablet; Preference

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; EBASTINE; LORATADINE; PLACEBO; WATER;

ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; FEMALE; GERMANY; HUMAN; INDIVIDUALIZATION; INTERVIEW; ITALY; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TABLET FORMULATION; TASTE PREFERENCE; TREATMENT OUTCOME;

EID: 49449088499     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.3.381     Document Type: Article

References (30)

1. Ratner P, Falqués M, Chuecos F et al. Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Int. Arch. Allergy Immunol. 138, 312-318 (2005).
2. Hampel F Jr, Howland W 3rd, Van Bavel J et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J. Investig. Allergol. Clin. Immunol. 14, 56-63 (2004).
3. Hurst M, Spencer CM. Ebastine - an update of its use in allergic disorders. Drugs 59, 981-1006 (2000).
4. Bousquet J, Gaudano EM, Palma-Carlos AG et al. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy 54, 562-568 (1999).
5. Davies RJ. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clin. Drug Invest. 16, 413-420 (1998).
6. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 52, 20-25 (1996).
7. Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonai allergic rhinitis in adults. Ann. Allergy Asthma Immunol. 76, 507-512 (1996).
8. Salvà M, Carreño B, Pintos M et al. Phase I, single dose, open-label, randomized, crossover bioequivalence studies of ebastine 10 and 20 mg regular tablets vs. 10 and 20 mg fast-dissolving tablets in healthy male volunteers. J. Invest. Allergol. Clin. Immunol. 14(4 Suppl. 1), S5 (2004).
9. Lang DM. Management of allergic rhinitis. Geriatric Times 3(2), March/April (2002).
10. D'Arcy PF. Oesophageal problems with tablets and capsules. Pharmacol. Int. 5, 109 (1984).
11. Roger A, Fortea J, Artés M, Montilla L. Acceptability and preference of the placebo fast dissolving tablet vs placebo regular tablets of ebastine in consumers of oral antihistamines with allergic rhinitis. Pharmaceutical Care (Spain) 7, 159 (2005).
12. Bousquet, J, van Cauwenberge P, Khaltaev N; and the Workshop Expert Panel. Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland. Allergy 57(12), 841-855 (2002).
13. Roger A, Galván J, Plazas MJ et al. Ebaflas doctors study. Barometer survey of acceptance of an oral freeze-dried pharmaceutical form in allergic patients. Patient satisfaction and expectations. Allergol. Immunopathol. 34 (3), 107-112 (2006).
14. Roger A, Fortea J, Artés M et al. Attributes for preference of new fast dissolving tablet (FDT) formulation of ebastine in patients with allergy. Value Health 8 (6), A23 (2005).
15. Roger A, Fortea. J, Artés M et al. Perception of the fast onset of action with ebastine fast dissolving tablet in allergic rhinitis patients. Pharmaceutical Care (Spain) 7, 157 (2005).
16. Juniper EF. The impact of patient compliance on effective asthma management. Curr. Opin Pulm. Med. 9(1), S8-S10 (2003).
17. Diamond R. Drugs and the quality of life: the patient's point of view. J. Clin. Psychiatry 46, 29-35 (1985).
18. Marple BF, Fornadley JA, Patel AA et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol. Head Neck Surg. 136(Suppl. 6), S107-S124 (2007).
19. Stern L, Berman J, Lumry W et al. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Ann. Allergy Asthma Immunol. 97(3), 402-408 (2006).
20. Dowson AJ, Charlesworth BR. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int. J. Clin. Pract. 57(7), 573-576 (2003).
21. Slowson M, Slowson S. What to do when patients cannot swallow their medications. Pharm. Times 51, 90-96 (1985).
22. Doheny K. You really expect me to swallow those horse pills? Am. Drug. 208, 34-35 (1993).
23. Virley P, Yarwood. R. Zydis - a novel, fast-dissolving dosage form. Manuf. Chem. 61, 36-37 (1990).
24. Habib W, Khankari R, Hontz J. Fast-dissolving drug delivery systems, critical review in therapeutics. Drug Carrier Systems 17(1), 61-72 (2000).
25. Fox DA. Rapid-dissolving dosage forms: an expanding therapeutic approach. Presented at: The 1996 Drug Delivery Systems Workshop at the Institute of International Research (1996).
26. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol. 50, 375-382 (1998).
27. Andersen O, Zweidorff OK, Hjelde T et al. Problems when swallowing tablets. A questionnaire study from general practice. Tidsskr. Nor. Laegeforen. 115(8), 947-949 (1995).
28. Palop-Larrea V, Martínez-Mir I. Adherencia al tratamiento en el paciente anciano. Inf. Ter. Sist. Nac. Salud. 28, 113-120 (2004).
29. Jay S, Litt IF, Durant RH. Compliance with therapeutic regimens. J. Adolesc. Health Care 5 (2), 124-136 (1984).
30. Haynes RB, Montague P, Oliver T et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst. Rev. 3, 1-26 (2000).